



## Viscera Labs Announces Receipt of Issue Notification from the USPTO

PARSIPPANY, NJ – February 8, 2023 – Viscera Labs, Inc. today announced that it had received an Issue Notification from the United States Patent and Trademark Office (USPTO) for its patent application on behalf of claims are directed to an oral drug delivery system. The application will issue as U.S. Patent No. 11,590,161 on February 28, 2023.

Published studies suggest that bile acid sequestrants may have clinical utility in bile acid-mediated conditions such as bile acid malabsorption diarrhea<sup>1</sup>. However, existing formulations of bile acid sequestrants are suboptimal and hence inadequate for these conditions. Viscera Labs is developing VL-001 to improve the efficacy, safety, and tolerability of colestevlam in bile acid-mediated conditions.

### References

1. Beigel F, et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. *J Crohns Colitis*. 2014 Nov; 8(11): 1471-9.

### About Viscera Labs

Viscera Labs is an innovative pharmaceutical company focused on developing novel and cost-effective therapeutic agents for bile acid-mediated disorders.